Exicure (XCUR) Non-Current Deffered Revenue (2016 - 2022)

Exicure's (XCUR) quarterly Non-Current Deffered Revenue came in at $9.0 million in Q2 2022, down 10.05% on a QoQ basis from $10.0 million in Q1 2022.

Exicure (XCUR) Non-Current Deffered Revenue (2016 - 2022) Analysis & Trends

Exicure (XCUR) has 4 years of Non-Current Deffered Revenue data on file, last reported at $9.0 million in Q2 2022.

Quarterly Non-Current Deffered Revenue changed N/A year-over-year to $9.0 million in Q2 2022, while the trailing twelve-month figure through Jun 2022 was $9.0 million (changed N/A YoY) and the FY2021 annual result came in at $11.5 million, changed N/A from the prior year.
Non-Current Deffered Revenue fell to $9.0 million in Q2 2022, from $10.0 million in the prior quarter.
In the past five years, Non-Current Deffered Revenue ranged from a high of $16.9 million in Q3 2021 to a low of $3.0 million in Q4 2019.
A 3-year average of $10.1 million and a median of $10.0 million in 2022 frame the typical range for Non-Current Deffered Revenue.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Deffered Revenue (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	220.40 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	147.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	Exicure	7.27 Mn	7.27 Mn	-	-

Download Data